PMID: 42251860

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Aroda Vanita R, Buzzetti Raffaella, Dalskov Stine-Mathilde, Jain Akshay B, Larsen Jonas Hughes, Mathieu Chantal, Pratley Richard E, Videmark Alex, Watt Torquil, Buse John B

The lancet. Diabetes & endocrinology · 2026

Vol. 14, Issue 8, pp. 649-661

View on PubMed DOI

This entry links to third-party literature. For research use only.

HumansDiabetes Mellitus, Type 2SemaglutideDouble-Blind MethodFemaleMaleMiddle AgedHypoglycemic AgentsAdultGlucagon-Like Peptides

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.